Ascierto, Paolo A <br/><br/>
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  02 2020 
 - 33-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2019.11.016  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Benzimidazoles--administration & dosage<br/>Carbamates--administration & dosage<br/>Diarrhea--chemically induced<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mutation<br/>Nausea--chemically induced<br/>Outcome Assessment, Health Care--methods<br/>Prognosis<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Skin Neoplasms--drug therapy<br/>Sulfonamides--administration & dosage<br/>Vemurafenib--administration & dosage<br/>Vomiting--chemically induced